Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
1.
Exp Dermatol ; 33(1): e15012, 2024 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-38284204

RESUMEN

Phototherapy is a useful treatment modality for atopic dermatitis (AD). This is a prospective randomised double-blind study comparing the clinical efficacy of combined ultraviolet-A (UVA)/narrowband ultraviolet-B (NBUVB) versus NBUVB phototherapy in the treatment of chronic AD. Patients with moderate-to-severe AD were randomised to receive either UVA/NBUVB or NBUVB phototherapy twice weekly over 12 weeks. At baseline, weeks 6 and 12, Eczema Area And Severity Index (EASI), itch score and adverse effects were assessed. At baseline and week 12, disease-related quality of life was evaluated using the Dermatology Life Quality Index (DLQI). Nine patients were randomised to receive UVA/NBUVB and 10 received NBUVB. At week 12, both groups showed significant improvement in EASI and itch scores (p < 0.05). Significant improvement in DLQI was seen in the UVA/NBUVB arm (p = 0.009) with a trend towards improvement in the NBUVB arm (p = 0.11). The efficacy of both modalities were comparable, as were reported adverse effects aside from skin dryness which was higher in the NBUVB arm (40% vs. 0%, p = 0.033). Combined UVA/NBUVB and NBUVB phototherapy have comparable clinical efficacy and safety in the treatment of chronic AD. NBUVB may induce greater skin dryness.


Asunto(s)
Dermatitis Atópica , Eccema , Terapia Ultravioleta , Humanos , Dermatitis Atópica/radioterapia , Estudios Prospectivos , Método Doble Ciego , Calidad de Vida , Terapia Ultravioleta/efectos adversos , Fototerapia , Prurito/etiología , Prurito/radioterapia , Resultado del Tratamiento
2.
Photodermatol Photoimmunol Photomed ; 39(4): 343-350, 2023 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-36345565

RESUMEN

BACKGROUND: Previous studies regarding the risk of skin malignancy with NBUVB have been performed in Caucasian patients, but few studies have been conducted in Asians. AIM: The aim of the study was to determine the risk of skin cancer in Asian patients with psoriasis and vitiligo receiving NBUVB phototherapy. METHODS: We performed a 9-year retrospective study including all patients with psoriasis and vitiligo receiving NBUVB (either 311 nm wavelength through cabin phototherapy or 308 nm through excimer lamp phototherapy) at the National Skin Centre. We matched the identification numbers of patients to the National Registry of Diseases Office database and collected data on all skin cancers diagnosed. RESULTS: A total of 3730 patients were included. During the course of the study, 12 cases of skin cancer were diagnosed, of which 10 were basal cell carcinomas, and 2 were squamous cell carcinomas. No cases of melanoma were detected in the study. The age-standardized incidence of skin cancer in psoriasis and vitiligo patients who received phototherapy was 47.5 and 26.5, respectively, which is higher than the incidence of skin cancers in the general population. Risk of skin malignancy was positively correlated with the cumulative (p = .008) and maximum dose of phototherapy (p = .011) as well as previous systemic treatments (p = .006). LIMITATIONS: Limitations include a relatively short follow-up period as well as the lack of quantification of solar exposure. CONCLUSIONS: NBUVB phototherapy in Asian skin increases the risk of skin malignancy. The risk of skin malignancy is higher with psoriasis patients, greater cumulative and maximal dose of phototherapy as well as the use of systemic therapy. Despite the increased risk, the absolute number of skin malignancies remains low, especially for vitiligo patients, with no cases of melanoma diagnosed-a reassuring finding that phototherapy remains a safe alternative in the treatment of psoriasis and vitiligo.


Asunto(s)
Melanoma , Psoriasis , Neoplasias Cutáneas , Terapia Ultravioleta , Vitíligo , Humanos , Estudios Retrospectivos , Vitíligo/epidemiología , Incidencia , Terapia Ultravioleta/efectos adversos , Fototerapia/efectos adversos , Psoriasis/complicaciones , Psoriasis/epidemiología , Psoriasis/radioterapia , Neoplasias Cutáneas/epidemiología , Neoplasias Cutáneas/etiología , Melanoma/epidemiología , Melanoma/radioterapia , Resultado del Tratamiento
3.
Am J Clin Dermatol ; 23(3): 267-275, 2022 May.
Artículo en Inglés | MEDLINE | ID: mdl-35246808

RESUMEN

BACKGROUND: Previous studies have shown that serum 25-hydroxyvitamin D (25(OH)D) may be associated with atopic dermatitis (AD), and that vitamin D (VD) supplementation may decrease AD severity. OBJECTIVE: The aim of this study was to investigate the association between serum 25(OH)D level and AD, and the effect of VD supplementation on AD severity, while providing stratified analyses based on latitude and region. METHODS: A systematic review was performed on all published studies in MEDLINE, Embase, and Cochrane Library databases that analyzed effects of serum 25(OH)D and VD supplementation on AD. RESULTS: This systematic review and meta-analysis includes 20 studies with 1882 cases of AD. We found significantly lower 25(OH)D levels in AD patients compared with healthy controls (HC) (p < 0.001), significantly lower 25(OH)D levels in severe AD compared with both mild and moderate AD (p < 0.001), and VD supplementation improved AD symptoms (p < 0.001). LIMITATIONS: Factors like seasonal and environmental changes, sunlight exposure, and cultural practices may confound the relationship between serum 25(OH)D and AD severity. There are limited randomized controlled trials that assess this association. CONCLUSION: Overall, lower serum 25(OH)D is associated with more severe AD, and VD supplementation may help lower AD severity. Further research is needed to confirm the presence and direction of causality of the relationship between VD and AD pathogenesis.


Asunto(s)
Dermatitis Atópica , Dermatitis Atópica/diagnóstico , Suplementos Dietéticos , Humanos , Vitamina D , Vitaminas
5.
Am J Clin Dermatol ; 17(2): 113-23, 2016 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-26547919

RESUMEN

BACKGROUND: Laboratory and animals studies have suggested a possible protective effect of coffee consumption on the development of melanoma. However, the results of epidemiological studies investigating this association have been inconclusive. OBJECTIVE: A systematic review and meta-analysis of published studies was conducted to evaluate any association between coffee consumption and melanoma. METHODS: Observational studies were searched for in MEDLINE, EMBASE, and the Cochrane Central Register from inception to September 1, 2015. The Meta-analysis Of Observational Studies in Epidemiology (MOOSE) guidelines were followed in conducting this study. RESULTS: We identified nine observational studies with a total of 927,173 study participants, of which 3787 had melanoma. With random-effects modeling, the pooled relative risks (RR) for melanoma among regular coffee drinkers was 0.75 (95 % confidence interval [CI] 0.63-0.89, p = 0.001) compared with controls. Visual inspection of a funnel plot suggested publication bias, although Egger's test (p = 0.981) delineated no small-study effects. The pooled relative risks for melanoma among decaffeinated coffee drinkers was, however, not statistically significant at 0.92 (95 % CI 0.82-1.05, p = 0.215). CONCLUSION: There is some evidence for the beneficial effects of regular coffee consumption on melanoma. More prospective cohort studies with systematic quantification of coffee consumption would be necessary to further elucidate this association.


Asunto(s)
Cafeína/metabolismo , Café/química , Melanoma/epidemiología , Melanoma/prevención & control , Neoplasias Cutáneas/epidemiología , Neoplasias Cutáneas/prevención & control , Quimioprevención , Ácido Clorogénico/análogos & derivados , Ácido Clorogénico/metabolismo , Diterpenos/metabolismo , Humanos , Masculino , Estudios Observacionales como Asunto , Sesgo de Publicación , Ácido Quínico/análogos & derivados , Ácido Quínico/metabolismo , Factores de Riesgo , Piel/efectos de la radiación , Rayos Ultravioleta/efectos adversos
6.
Pediatr Dermatol ; 33(1): 62-8, 2016.
Artículo en Inglés | MEDLINE | ID: mdl-26645992

RESUMEN

BACKGROUND: Neonatal blue light phototherapy (NBLP) is an established method of managing neonatal hyperbilirubinemia. Approximately 5% of newborns are exposed to NBLP. Evidence of whether NBLP predisposes to the development of melanocytic nevi later in life has been conflicting. OBJECTIVES: The goal of the current study was to conduct a systematic review and meta-analysis to quantitatively assess the effect of NBLP on melanocytic nevus count. METHODS: We searched for observational studies in Medline, EMBASE, and the Cochrane Central Register from their inception to April 15, 2015. Meta-analysis of Observational Studies in Epidemiology guidelines were followed. DerSimonian and Laird random-effects models were used to calculate the weighted mean difference (WMD). Publication bias was assessed using a funnel plot and the Egger's test. RESULTS: Five studies with a total of 2,921 subjects were included, of whom 642 underwent NBLP. With random-effects modeling, those who had previous NBLP did not have a significantly higher mean number of melanocytic nevi (WMD = 0.32 [95% confidence interval -0.67, 1.31], p = 0.53). Visual inspection of the funnel plot suggested potential publication bias, although the Egger's test (p = 0.09) indicated no small-study effect. CONCLUSION: There was no evidence that prior NBLP exposure significantly increased the number of melanocytic nevi. Available evidence has not revealed any cause for major concern for NBLP. Other risk factors such as exposure to sunlight, childhood history of sunburn, and fair skin complexion might play a greater role in the development of melanocytic nevi in childhood.


Asunto(s)
Nevo Pigmentado/etiología , Fototerapia/efectos adversos , Neoplasias Cutáneas/etiología , Femenino , Humanos , Hiperbilirrubinemia/terapia , Recién Nacido , Masculino , Nevo Pigmentado/patología , Factores de Riesgo , Neoplasias Cutáneas/patología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA